The management of gout at an academic healthcare center in Beijing: A physician survey

Journal of Rheumatology

Volumn 33, Issue 10, 2006, Pages 2041-2049

  Fang, Weigang ^a   Zeng, Xuejun ^a   Li, Mengtao ^a   Chen, Lan X ^b   Schumacher Jr , H Ralph ^b   Zhang, Fengchun ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Continuing medical education; Gout; Synovial fluid; Teaching

Indexed keywords

ANTIGOUT AGENT; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; URIC ACID LOWERING AGENT;

CHINA; CONTINUING EDUCATION; GOUT; HEALTH CENTER; HEALTH SURVEY; HUMAN; JOINT EFFUSION; KIDNEY DISEASE; LOGISTIC REGRESSION ANALYSIS; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MEDICAL SPECIALIST; MULTIVARIATE ANALYSIS; PHYSICIAN; PRIORITY JOURNAL; RESIDENT; REVIEW; SYNOVIAL FLUID; TEACHING HOSPITAL; TREATMENT INDICATION; URIC ACID BLOOD LEVEL; WORK EXPERIENCE;

ACADEMIC MEDICAL CENTERS; ADRENAL CORTEX HORMONES; ADRENOCORTICOTROPIC HORMONE; ADULT; CHINA; COLCHICINE; DECISION MAKING; EDUCATION, MEDICAL, CONTINUING; FEMALE; GOUT; GOUT SUPPRESSANTS; HEALTH CARE SURVEYS; HUMANS; MALE; MEDICINE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYSICIAN'S PRACTICE PATTERNS; SPECIALIZATION; SPECIALTIES, MEDICAL; SYNOVIAL FLUID; URIC ACID; URICOSURIC AGENTS;

EID: 33750022818     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Chang HY, Pan WH, Yen WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-%). J Rheumatol 2001;28:1640-6.
2. Chen S, Du H, Wang Y, Xu L. The epidemiology study of hyperuricemia und gout in a community population of Huangpu District in Shanghai. Chin Med J Engl 1998;111:228-30.
3. Chang CJ. Gout and gouty arthritis. Chin Med J 1959;78:214-9.
4. Yang XY, Tang FL, Yin PD. The trend of proportion among inpatients with gout in 21 hospitals during the past 15 years. Zhonghua Liu Xing Bing Xue Za Zhi 1996;17:10-2.
5. Wang Q, Chen R, Du L, Zeng Q. An epidemiological and clinical study of primary gout. Zhonghua Nei Ke Za Zhi 2001;40:313-5.
6. Zeng Q, Wang Q, Chen R, Xiao Z, Huang S, Xu J. Primary gout in Shantou: a clinical and epidemiological study. Chin Med J Engl 2003;116:66-9.
7. Wigley RD, Zhang NZ, Zeng QY, et al. Rheumatic diseases in China: ILAR-China study comparing the prevalence of rheumatic symptoms in northern and southern rural populations. J Rheumatol 1994;21:1484-90.
8. Zeng Q, Huang S, Chen R. 10-year epidemiological study on rheumatic diseases in Shanlou area. Zhonghua Nei Ke Za Zhi 1997;36:193-7.
9. Dai SM, Han XH, Zhao DB, Shi YQ, Liu Y, Meng JM. Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis. and gout in Shanghai. China: a COPCORD study. J Rheumatol 2003;30:2245-51.
10. Schlesinger N, Schumacher HR, Jr. Gout: Can management be improved? Curr Opin Rheumatol 2001;13:240-4.
11. Kim KY, Schumacher HR, Hunsche E, Wertheimer AI, Kong SX. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003;25:1593-617.
12. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
13. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-51.
14. Terkeltaub RA. Clinical practice. Gout. N Engl J Med 2003;349:1647-55.
15. Wortmann R, Kelley WN. Gout and hyperuricemia. In: Harris ED Jr. Ruddy S, Sledge CB, et al. editors. Kelley's textbook of rheumatology. Philadelphia: Elsevier Saunders: 2005:1402-29.
16. Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005;17:319-24.
17. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician 1999;59:925-34.
18. Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum 2004;50:937-43.
19. Schumacher HR Jr. Sieck MS, Rothfuss S, et al. Reproducibility of synovial fluid analyses. A study among four laboratories. Arthritis Rheum 1986;29:770-4.
20. Nakayama DA, Barthelemy C, Carrera G, Lightfoot RW Jr. Wortmann RL. Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum 1984;27:468-71.
21. Eisenberg JM, Schumacher HR, Davidson PK, Kaufmann L. Usefulness of synovial fluid analysis in the evaluation of joint effusions. Use of threshold analysis and likelihood ratios to assess a diagnostic test. Arch Intern Med 1984;144:715-9.
22. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust NZ J Med 1987;17:301-4.
23. Arnold MH, Preston SJ, Buchanan WW. Comparison of the natural history of untreated acute gouty arthritis vs acute gouty arthritis treated with non-steroidal-anti-inflammatory drugs. Br J Clin Pharmacol 1988;26:488-9.
24. Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990;19:329-36.
25. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988;31:803-5.
26. Ritter J, Kerr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994;21:696-9.
27. Taylor CT, Brooks NC, Kelley KW. Corticotropin for acute management of gout. Ann Pharmacother 2001;35:365-8.
28. Rozenberg S, Lang T, Laatar A, Koeger AC, Orcel P, Bourgerois P. Diversity of opinions on the management of gout in France. A survey of 750 rheumatologists. Rev Rhum Engl Ed 1996;63:255-61.
29. Tomita M, Mizuno S, Yumanaku H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000;10:403-9.
30. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005;45:28-33.
31. Fam AG. Should patients with interval gout be treated with urate lowering drugs? J Rheumatol 1995;22:1621-3.
32. Ferraz MB, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995;22:908-14.
33. Mikuls TR, Saag KG. Gout treatment: What is evidence-based and how do we determine and promote optimized clinical care? Curr Rheumatol Rep 2005;7:242-9.
34. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology Oxford 2005;44:1038-42.